H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.176 HKD 7.32% Market Closed
Market Cap: 88.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huakang Biomedical Holdings Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Income from Continuing Operations
-ÂĄ5.8m
CAGR 3-Years
21%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Income from Continuing Operations
-HK$56.9m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
-5%
K
Kelfred Holdings Ltd
HKEX:1134
Income from Continuing Operations
HK$1.4m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Income from Continuing Operations
HK$37.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
0%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Income from Continuing Operations
$45.1m
CAGR 3-Years
85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Huakang Biomedical Holdings Co Ltd
Glance View

Market Cap
88.1m HKD
Industry
Health Care

Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.

Intrinsic Value
0.085 HKD
Overvaluation 52%
Intrinsic Value
Price
H

See Also

What is Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
-5.8m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations amounts to -5.8m CNY.

What is Huakang Biomedical Holdings Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-66%

Over the last year, the Income from Continuing Operations growth was -88%. The average annual Income from Continuing Operations growth rates for Huakang Biomedical Holdings Co Ltd have been 21% over the past three years , -66% over the past five years .

Back to Top